ProQR Therapeutics NV
(NASDAQ : PRQR)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
MRNAModerna, Inc. -3.63%62.610.0%$958.21m
NVAXNovavax, Inc. -2.02%94.36251.8%$764.51m
AMGNAmgen, Inc. -1.04%249.041.3%$693.79m
REGNRegeneron Pharmaceuticals, Inc. -3.09%620.862.5%$663.02m
GILDGilead Sciences, Inc. 2.16%76.321.0%$630.80m
BIIBBiogen, Inc. 0.07%278.881.6%$601.57m
VRTXVertex Pharmaceuticals, Inc. -0.32%294.451.9%$475.52m
ILMNIllumina, Inc. -0.63%370.253.5%$301.18m
VXRTVaxart, Inc. -2.56%7.980.0%$286.91m
ALXNAlexion Pharmaceuticals, Inc. 0.32%108.822.0%$217.19m
BMRNBioMarin Pharmaceutical, Inc. -0.59%126.064.3%$206.81m
SRNESorrento Therapeutics, Inc. 4.00%8.061.8%$192.86m
SGENSeattle Genetics, Inc. -3.76%174.356.1%$192.39m
IMMUImmunomedics, Inc. -2.32%41.3211.0%$177.00m
ALNYAlnylam Pharmaceuticals, Inc. 2.03%162.258.5%$166.65m

Company Profile

ProQR Therapeutics NV operates as a biopharmaceutical company, which engages in the discovery and development of Ribonucleic Acid RNA based therapeutics for the treatment of genetic disorders. Its initial focus is on the development of a disease-modifying therapy for the treatment of cystic fibrosis. The company was founded by Daniel de Boer, Gerard Platenburg, Henri Termeer and Dinko Valerio on February 21, 2012 and is headquartered in Leiden, the Netherlands.